Generali Asset Management SPA SGR Reduces Holdings in Corteva, Inc. $CTVA

Generali Asset Management SPA SGR trimmed its stake in Corteva, Inc. (NYSE:CTVA) by 20.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,219 shares of the company’s stock after selling 10,494 shares during the period. Generali Asset Management SPA SGR’s holdings in Corteva were worth $2,763,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Reynders McVeigh Capital Management LLC boosted its stake in Corteva by 2.9% during the 4th quarter. Reynders McVeigh Capital Management LLC now owns 5,686 shares of the company’s stock worth $381,000 after purchasing an additional 160 shares during the period. Fox Run Management L.L.C. boosted its stake in Corteva by 5.1% during the 3rd quarter. Fox Run Management L.L.C. now owns 3,361 shares of the company’s stock worth $227,000 after purchasing an additional 164 shares during the period. IFG Advisory LLC boosted its stake in Corteva by 1.7% during the 3rd quarter. IFG Advisory LLC now owns 9,764 shares of the company’s stock worth $660,000 after purchasing an additional 166 shares during the period. Kelleher Financial Advisors boosted its stake in Corteva by 3.8% during the 3rd quarter. Kelleher Financial Advisors now owns 4,594 shares of the company’s stock worth $311,000 after purchasing an additional 170 shares during the period. Finally, Rosenberg Matthew Hamilton boosted its stake in Corteva by 6.1% during the 4th quarter. Rosenberg Matthew Hamilton now owns 2,969 shares of the company’s stock worth $199,000 after purchasing an additional 172 shares during the period. 81.54% of the stock is owned by hedge funds and other institutional investors.

Corteva Stock Up 2.6%

Shares of Corteva stock opened at $81.10 on Friday. The company has a market cap of $54.24 billion, a P/E ratio of 47.70, a PEG ratio of 2.77 and a beta of 0.59. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.96 and a current ratio of 1.47. Corteva, Inc. has a one year low of $60.53 and a one year high of $85.63. The firm has a fifty day moving average of $80.68 and a two-hundred day moving average of $72.61.

Corteva (NYSE:CTVA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.18 by $0.32. The company had revenue of $4.91 billion during the quarter, compared to the consensus estimate of $4.64 billion. Corteva had a net margin of 6.50% and a return on equity of 9.95%. Corteva’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.13 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, analysts forecast that Corteva, Inc. will post 3.67 earnings per share for the current year.

Corteva Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 15th. Shareholders of record on Monday, June 1st will be given a dividend of $0.18 per share. The ex-dividend date is Monday, June 1st. This represents a $0.72 dividend on an annualized basis and a yield of 0.9%. Corteva’s dividend payout ratio is presently 42.35%.

Insider Buying and Selling

In other Corteva news, insider Brian Titus sold 8,311 shares of the company’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $76.55, for a total transaction of $636,207.05. Following the completion of the transaction, the insider owned 8,090 shares in the company, valued at approximately $619,289.50. This represents a 50.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.15% of the company’s stock.

Wall Street Analysts Forecast Growth

CTVA has been the subject of a number of recent research reports. Berenberg Bank increased their price target on shares of Corteva from $68.00 to $78.00 and gave the stock a “hold” rating in a research note on Thursday, March 26th. Oppenheimer increased their price target on shares of Corteva from $86.00 to $89.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. BNP Paribas Exane increased their price target on shares of Corteva from $74.00 to $77.00 in a research note on Wednesday. UBS Group increased their price target on shares of Corteva from $88.00 to $90.00 and gave the stock a “neutral” rating in a research note on Thursday. Finally, CICC Research increased their price target on shares of Corteva from $70.00 to $80.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Thirteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.05.

Trending Headlines about Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Royal Bank of Canada raised Corteva’s price target to $97 from $95 and kept an outperform rating, signaling confidence in roughly 20% upside from recent levels. RBC Capital adjusts Corteva price target to $97 from $95, maintains outperform rating
• Positive Sentiment: Jefferies also increased its target on Corteva to $97 from $95, reinforcing a bullish view on the stock’s longer-term valuation. Jefferies adjusts price target on Corteva to $97 from $95
• Neutral Sentiment: UBS raised its target to $90 from $88 but kept a neutral rating, suggesting limited near-term conviction despite modest upside potential. UBS Group AG price target raise
• Neutral Sentiment: Citigroup lifted its target to $85 from $83 and maintained a neutral rating, indicating some valuation support but no strong bullish call. Citigroup Inc. price target raise
• Neutral Sentiment: Corteva said CEO Chuck Magro and CFO David Johnson will speak at the BMO Global Farm to Market Conference on May 14, a routine investor-relations event with limited immediate impact. Corteva to Participate in BMO Global Farm to Market Conference
• Neutral Sentiment: BNP Paribas Exane nudged its target higher to $77 from $74 but still implied downside from the stock’s recent trading range, making it a mixed signal. BNP Paribas adjusts price target on Corteva to $77 from $74

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.